Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 20, 2026, 12:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Vaginal Progesterone gel. Clear all

Conditions: Congenital Heart Disease, Periventricular Leucomalacia, Brain Development, Cardiac Surgery, Neurodevelopmental Disability, Fetal Neuroprotection
Interventions: Progesterone, Vaginal lubricant; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infertility
Interventions: DR-2011, Crinone 8%; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 1,297 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 29
States / cities: Tarzana, California • West Los Angeles, California • Westlake, California + 26 more

Conditions: Infertility
Interventions: DR-2011, Progesterone 8% Vaginal Gel; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Coronary Heart Disease
Interventions: Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Infertility
Interventions: Vaginal progesterone gel (Crinone® 8%), Intramuscular Progesterone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infertility
Interventions: Crinone 8% Vaginal Gel, Intramuscular Progesterone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 39 Years · Female only
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Premature Birth
Interventions: Vaginal Progesterone gel., fetal fibronectin swab., Placebo gel; Drug · Procedure
Lead sponsor: Obstetrix Medical Group; Industry
Eligibility: 18 Years to 60 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Jose, California

Conditions: Infertility
Interventions: Progesterone-IBSA Injectable Solution, Progesterone Vaginal Gel with Applicator, Placebo Vaginal gel with applicator, Placebo injectable solution; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 35 Years to 42 Years · Female only
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Tempe, Arizona • Encino, California • Los Angeles, California + 20 more

Conditions: Preterm Labor
Interventions: Experimental: Vaginal progesterone, Experimental: Topical progesterone, Experimental: Intramuscular progesterone; Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 17 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Polycystic Ovary Syndrome
Interventions: Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound, Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe, Intrauterine insemination or timed intercourse; Drug · Diagnostic Test · Other
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Premature Birth
Interventions: Cervical cerclage, Vaginal progesterone; Procedure · Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Preterm Delivery, Short Cervix, Short Uterine Cervical Length
Interventions: progesterone, placebo; Drug
Lead sponsor: Juniper Pharmaceuticals, Inc.; Industry
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 465 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 27
States / cities: Mobile, Alabama • Phoenix, Arizona • Orange, California + 21 more

Conditions: HIV Prevention
Interventions: Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Norfolk, Virginia

Conditions: Pregnancy
Interventions: 8% progesterone vaginal gel, Placebo Vaginal Gel; Drug
Lead sponsor: Juniper Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 636 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 45
States / cities: Mobile, Alabama • Tucson, Arizona • Colton, California + 39 more

Conditions: Labor, Premature
Interventions: Vaginal progesterone gel, Placebo vaginal gel; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Infertility, Pregnancy
Interventions: Crinone vaginal progesterone gel, Placebo vaginal gel; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Charlotte, North Carolina

Search by objective public record fields.

Randomized Trial of Maternal Progesterone Therapy

A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization

Comparison of DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement

Relationship Between the Menstrual Cycle and Heart Disease in Women

Comparison of Vaginal and Intramuscular Progesterone in Vitrified-warmed Blastocyst Transfer Cycles

Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)

Vaginal Progesterone in Twins With Short Cervix

Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor

Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole

Cerclage On LOw Risk Singletons: Cervical Cerclage for Prevention of Spontaneous Preterm Birth in Low Risk Singleton Pregnancies With Short Cervix

PREGNANT Short Cervix Trial

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

Vaginal Progesterone as a Treatment for Women Active Preterm Labor

Sexual Absorption of Vaginal Progesterone